Research programme: slow off-rate modified aptamers - SomaLogic/Otsuka

Drug Profile

Research programme: slow off-rate modified aptamers - SomaLogic/Otsuka

Alternative Names: SL1026; SOMAmer®

Latest Information Update: 12 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SomaLogic
  • Developer Otsuka Pharmaceutical; SomaLogic
  • Class Nucleotide aptamers; Peptide aptamers
  • Mechanism of Action Interleukin 6 inhibitors; Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 07 Dec 2015 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)
  • 10 Aug 2015 Early research into SOMAmer theraputics is ongoing
  • 10 Aug 2015 Otsuka Pharmaceutical extended its initial collaboration agreement with SomaLogic to continue the development of SOMAmer® therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top